Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study

Tanguy-Schmidt, Aline;Rousselot, Philippe;Chalandon, Yves;Cayuela, Jean-Michel;Thomas, Xavier;et.al.
(2013) Biology of Blood and Marrow Transplantation — Vol. 19, n° 1, p. 150-155 (2013)

Files

pdfdocument.pdf
  • Restricted Access
  • Adobe PDF
  • 604.76 KB

Details

Authors
  • Tanguy-Schmidt, Aline
    Author
  • Rousselot, Philippe
    Author
  • Chalandon, Yves
    Author
  • Cayuela, Jean-Michel
    Author
  • Thomas, Xavier
    Author
Show more
Abstract
We report here the results of the GRAAPH-2003 trial with long-term follow-up in 45 patients with de novo Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Imatinib-based strategy improved the 4-year overall survival (OS) up to 52% versus 20% in the pre-imatinib LALA-94 trial (P = .0001). Despite the selection in patients who actually underwent transplantation, these results suggest that allogeneic or autologous stem cell transplants (SCTs) still have a place in overcoming the poor prognosis of Ph+ ALL in the era of imatinib therapy. OS was 50% after allogeneic SCT (24 patients), 33% in patients without a transplantation (9 patients), and 80% after autologous SCT (10 patients without allogeneic donor or >55 years, including 7 patients in complete molecular response).
Affiliations

Citations

Tanguy-Schmidt, A., Rousselot, P., Chalandon, Y., Cayuela, J.-M., Hayette, S., Vekemans, M.-C., Escoffre, M., Huguet, F., Réa, D., Delannoy, A., Cahn, J.-Y., Vernant, J.-P., Ifrah, N., Dombret, H., & Thomas, X. (2013). Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. Biology of Blood and Marrow Transplantation, 19(1), 150-155. https://doi.org/10.1016/j.bbmt.2012.08.021 (Original work published 2013)